Christoph Heinzen
Chief Operating Officer chez LIFEWATCH AG
Profil
Christoph Heinzen is the founder of Vivendy Therapeutics Ltd.
founded in 2006.
He is currently the Chief Operations Officer & CTO at LifeWatch GmbH since 2016 and also holds the position of Head-Project Management at Spirig AG.
Dr. Heinzen's former positions include Chief Executive Officer & General Manager at Inotech Biotechnologies AG and Head-OTC products Development at Galderma International SAS.
Dr. Heinzen's education includes a graduate degree and a doctorate from the Swiss Federal Institute of Technology.
Postes actifs de Christoph Heinzen
| Sociétés | Poste | Début |
|---|---|---|
| LIFEWATCH AG | Chief Operating Officer | 01/09/2016 |
| Spirig AG | Corporate Officer/Principal | - |
Anciens postes connus de Christoph Heinzen
| Sociétés | Poste | Fin |
|---|---|---|
Galderma International SAS
 Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Vivendy Therapeutics Ltd.
 Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Founder | - |
Inotech Biotechnologies AG
 Inotech Biotechnologies AG Pharmaceuticals: MajorHealth Technology Inotech Biotechnologies AG specializes in research, development and production of biopharmaceuticals products. It helps people by creating apps and gadgets to reach their health and fitness goals. The company is headquartered in Basel, Switzerland. | Chief Executive Officer | - |
Formation de Christoph Heinzen
| Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
LifeWatch GmbH
 LifeWatch GmbH Medical SpecialtiesHealth Technology LifeWatch GmbH engages in the acquisition, holding, and management of companies that specialize in research, development, manufacture, sale, and distribution of equipment in the fields of electronics, medicine, as well as computer and engineering. It also provides telemedical services. The company was founded on July 18, 2001 and is headquartered in Zug, Switzerland. | Health Technology |
Inotech Biotechnologies AG
Inotech Biotechnologies AG Pharmaceuticals: MajorHealth Technology Inotech Biotechnologies AG specializes in research, development and production of biopharmaceuticals products. It helps people by creating apps and gadgets to reach their health and fitness goals. The company is headquartered in Basel, Switzerland. | Health Technology |
Galderma International SAS
Galderma International SAS Pharmaceuticals: MajorHealth Technology Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France. | Health Technology |
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Health Services |
| Spirig AG |
